Barry R. Walker
Founder at American Society of Hypertension
Profile
Barry R.
Walker is the founder of American Society of Hypertension.
He worked as a Senior Vice President of Research & Development at Wyeth-Ayerst Research and as an Adjunct Associate Professor of Medicine at the University of Pennsylvania.
He also served as an Independent Non-Executive Director at Botanix Pharmaceuticals Ltd.
and as SVP-Regulatory & Clinical Development at Ceptaris Therapeutics, Inc. He holds a doctorate from The Trustees of Columbia University in The City of New York and an undergraduate degree from Yale University.
Barry R. Walker active positions
Companies | Position | Start |
---|---|---|
American Society of Hypertension | Founder | 2011-03-15 |
Former positions of Barry R. Walker
Companies | Position | End |
---|---|---|
University of Pennsylvania | Corporate Officer/Principal | - |
BOTANIX PHARMACEUTICALS LIMITED | Director/Board Member | 2011-08-18 |
Wyeth-Ayerst Research | Chief Tech/Sci/R&D Officer | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | General Counsel | 2011-03-21 |
Training of Barry R. Walker
The Trustees of Columbia University in The City of New York | Doctorate Degree |
Yale University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
BOTANIX PHARMACEUTICALS LIMITED | Health Technology |
Private companies | 3 |
---|---|
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Health Technology |
Wyeth-Ayerst Research | |
American Society of Hypertension |
- Stock Market
- Insiders
- Barry R. Walker